Core Viewpoint - The article emphasizes the importance of correctly selecting traditional Chinese medicine (TCM) for treating colds, as improper use can delay recovery and increase the risk of adverse reactions [1]. Group 1: Types of Colds - Colds can be categorized based on the type of wind and other pathogens or the individual's constitution, including wind-cold, wind-heat, summer-damp, and deficiency colds [1]. - Wind-cold colds are characterized by symptoms such as severe chills, mild fever, and nasal congestion, typically treated with warming and dispersing methods [2]. - Wind-heat colds present with more severe fever and throat pain, requiring cooling and dispersing treatments [3]. - Summer-damp colds occur in warmer months, often due to dampness and cold exposure, with symptoms including headache and gastrointestinal discomfort [4]. - Deficiency colds are common in the elderly or those with weakened immune systems, presenting with fatigue and recurrent colds [6]. - Seasonal colds, akin to influenza, have acute onset and strong contagiousness, necessitating detoxifying treatments [7]. Group 2: Common TCM Treatments - For wind-cold colds, common TCM remedies include: - Ganmao Qingre Granules, which contain ingredients like Schizonepeta and mint, effective for symptoms like headache and nasal discharge [2]. - Zheng Chaihu Granules, which help alleviate fever and body aches [2]. - Tongxuan Liupai Pills, suitable for coughs associated with wind-cold [2]. - For wind-heat colds, treatments include: - Yin Qiao Jie Du Tablets, effective for fever and sore throat [3]. - Shuanghuanglian Oral Liquid, which addresses symptoms of fever and cough [3]. - Sangju Ganmao Tablets, suitable for initial symptoms of wind-heat colds [3]. - For summer-damp colds, common remedies are: - Huoxiang Zhengqi Water, which helps with symptoms like nausea and abdominal discomfort [5]. - Baoji Pills, effective for gastrointestinal symptoms associated with summer-damp colds [5]. - For deficiency colds, Yipingfeng Granules are commonly used to strengthen the immune system [6]. - For seasonal colds, Lianhua Qingwen Capsules are recommended for their detoxifying properties [7]. Group 3: Medication Considerations - Patients should choose appropriate dosage forms of TCM based on personal needs, such as granules for children or capsules for those sensitive to taste [8]. - It is crucial to avoid overlapping medications with similar ingredients to prevent adverse reactions [8]. - Special populations, including children, pregnant women, and the elderly, should use medications cautiously and under guidance [8].

Core Viewpoint - The company Jinghua Pharmaceutical (002349.SZ) does not currently produce any drugs specifically for the treatment of respiratory syncytial virus (RSV) [1] Product Overview - The company's product Qingzhai Hu Yin Granules is used for symptoms such as fever, chills, headache, nasal congestion, sneezing, throat itching, cough, and limb soreness, suitable for initial stages of influenza and mild upper respiratory infections [1] - The product Wang's Baochi Pill is effective for pediatric conditions like milk stagnation, phlegm-induced seizures, cough with phlegm, reduced milk intake, diarrhea with fever, seasonal colds, as well as for adults with gastrointestinal issues [1] - The product Jin Qiao Mai Pian has functions of clearing heat and detoxifying, promoting pus discharge, and relieving cough and asthma, mainly used for acute lung abscess, acute and chronic bronchitis, asthma, and bacterial dysentery [1] - The product Ji Desheng Snake Medicine Tablets has effects of clearing heat and detoxifying, reducing swelling and relieving pain, treating snake and insect bites, and has unique efficacy against viral infections, bacterial infections, and immune deficiencies [1]

Core Viewpoint - The company demonstrates resilience and growth potential in a complex industry environment, with steady revenue growth, significant cash flow improvement, and enhanced competitiveness of core products, alongside advancing internationalization and R&D innovation [1]. Financial Performance - For the first half of 2025, the company achieved revenue of 731 million yuan, a year-on-year increase of 1.54%; net profit attributable to shareholders was 131 million yuan, with a net profit of 127 million yuan after excluding non-recurring gains and losses, indicating solid profitability in core operations [2]. - The net cash flow from operating activities surged by 31.87% to 128 million yuan, reflecting improved operational quality and enhanced capital management efficiency [2]. Core Product Strength - Sales revenue from traditional Chinese medicine preparations grew by 12.45% year-on-year to 287 million yuan, serving as a key support for performance [3]. - Key products such as "Wang's Baochi Pill," "Jide Sheng Snake Medicine Tablets," and "Zheng Chai Hu Drink Granules" continue to gain clinical and market recognition due to their unique efficacy and strong brand heritage [3]. - "Wang's Baochi Pill" was included in the "International Clinical Practice Guidelines for Functional Dyspepsia in Traditional Chinese Medicine (2025 Edition)," enhancing its international influence [3]. International Expansion - The company actively expanded its overseas market, achieving self-operated export sales of 11.3 million USD, a year-on-year increase of 16% [4]. - Several raw material drug varieties have received FDA and CEP certifications, gaining international quality recognition [4]. R&D and Capacity Development - The company places high importance on R&D investment, collaborating with universities on various pharmacological and clinical research projects [5]. - The approval of new indications for "Diphenhydramine Hydrochloride Tablets" by the National Medical Products Administration further enriches the product line [5]. - Projects for traditional Chinese medicine preparation production bases, GMP certification upgrades, and energy-saving renovations are progressing steadily, laying the foundation for future capacity release and quality upgrades [5]. Cost Reduction and Efficiency Improvement - Through process optimization, intelligent equipment upgrades, and procurement cost control, the company achieved cost reductions exceeding 5 million yuan in the first half of the year [6]. - A successful stock incentive plan was implemented in May, granting 15.494 million restricted shares to 105 core employees, effectively motivating the team for long-term development [6]. Social Responsibility - The company continues to promote the construction of GAP bases for Chinese medicinal materials in Gansu Longxi, adopting a "leading enterprise + base + cooperative" model to boost local farmers' income [7]. - During the reporting period, the company procured local medicinal materials worth 30.946 million yuan, creating over 70 jobs, showcasing the responsibility and commitment of state-owned enterprises [7].